Contemporary Oncology

home / authors / contemporary-oncology

Articles

Site Logo

Sam Donaldson Hosts Roundtable on End-of-Life Care for Cancer Patients

Contemporary Oncology
March 4th 2011

The National Comprehensive Cancer Network (NCCN) 15th Annual Meeting in March opened with a roundtable discussion on "Cancer Care at the End of Life: When is Enough Enough?"

Read More

Site Logo

The Proactive Patient: 10 Questions for Your Cancer Care Team

Contemporary Oncology
March 4th 2011

Ten Questions Every Patient Should be Asking

Read More

Site Logo

Fall FDA Updates

Contemporary Oncology
March 4th 2011

Read More

Site Logo

Further Winter 2010 FDA Updates

Contemporary Oncology
March 3rd 2011

Read More

Site Logo

Winter 2010 FDA Updates

Contemporary Oncology
March 3rd 2011

FDA updates from Winter 2010

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data